This study examines; along with current situation in Turkey, pharmaceutical pricing methods, reimbursement methods and basic health indicators, within the scope of changing pharmaceutical policies, in Turkey, reference countries and the United Kingdom, the implementations of which are of utmost importance for other countries.  Upon the research conducted, it was detected that the pharmaceutical pricing in Turkey has been performed on the basis of reference pricing system that takes Italy, Portugal, Spain, Greece and France as reference. The regulations regarding the reimbursement process are determined by SSI. The reimbursement system has been changed numerous times and the discount rates has incrementally risen. In pricing, on the other hand, drug companies face difficulties in economic terms because of the fact that price discount of high rates are implemented over the reference price and that the European currency of Euro is fixed at 2.  Moreover, it has also been recognized that certain drugs have been hard to find within the market and the patients’ access to medicines has become hindered.  Although it is natural for Turkey to put restrictions on drugs budget to ensure sustainable drug financing, in order to maintain the existence of pharmaceutical industry and protect the patients’ access to medicines; it would be more favorable in the development of the industry that the expectations of the stakeholders in the industry are taken into account in the policy making process. This would also help the already supported R&D activities to be sustainable as well. The positive and negative aspects of Turkey’s offering the least expensive medicine should be examined. Whether being the country to supply the least expensive medicine is the correct objective or not in the international arena should seriously be discussed. It is recommended that how this situation affects Turkey’s image in the outer world should be scrutinized.